Despite several efforts, only Tazemetostat has been approved for clinical usage as EZH2 inhibitor, with several such as CPI-1205, GSK126, and valemetostat still in clinical trials, and their translation to solid tumors like pancreatic cancer has been limited by modest efficacy, emergence of resistance mechanisms, lack of robust predictive biomarkers, and potential toxicity from off-target epigenetic effects (Yang et al. 2023). The gene discussed is EZH2; the disease is familial pancreatic carcinoma.